Spyre Therapeutics, Inc. granted stock options to purchase an aggregate of 51,300 shares of common stock to four non-executive employees as equity inducement awards. The grants were approved by the independent Compensation Committee of the Board of Directors on June 1, 2026, and were material to each employee's acceptance of employment with Spyre. The awards were issued under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $70.54, which was the closing price per share of Spyre's common stock as reported by Nasdaq on June 1, 2026. The options are subject to the terms of the 2018 Plan.

Vesting Schedule

The options granted to the employees shall vest and become exercisable according to a specific schedule. One-fourth (1/4th) of the shares subject to the respective options will vest on the first anniversary of the employee's start date. Thereafter, one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly. In all cases, vesting is subject to continuous service with Spyre through the applicable vesting dates.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.